ARGUN AKCAKANAT

TitleAssistant Professor
InstitutionMD Anderson
DepartmentInvestigational Cancer Therapeutics
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Owusu-Brackett N, Zhao M, Akcakanat A, Evans KW, Yuca E, Dumbrava EI, Janku F, Meric-Bernstam F. Targeting PI3Kß alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. Oncotarget. 2020 Mar 17; 11(11):969-981. PMID: 32215185.
      Citations:    Fields:    
    2. Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Tapia C, Rizvi YQ, Dumbrava EI, Janku F, Meric-Bernstam F. TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. Oncotarget. 2019 Aug 20; 10(49):5011-5019. PMID: 31489111.
      Citations:    Fields:    
    3. Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78. PMID: 31277699.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    4. Akcakanat A, Meric-Bernstam F. MK-2206 window of opportunity study in breast cancer. Ann Transl Med. 2018 Nov; 6(Suppl 1):S57. PMID: 30613632.
      Citations:    
    5. Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6468-6477. PMID: 29093017.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    6. Woo SU, Sangai T, Akcakanat A, Chen H, Wei C, Meric-Bernstam F. Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer. Oncogenesis. 2017 Oct 09; 6(10):e385. PMID: 28991258.
      Citations:    
    7. Arango NP, Yuca E, Zhao M, Evans KW, Scott S, Kim C, Gonzalez-Angulo AM, Janku F, Ueno NT, Tripathy D, Akcakanat A, Naing A, Meric-Bernstam F. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Res. 2017 Aug 15; 19(1):93. PMID: 28810913.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    8. McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2016; 11(3):e0151121. PMID: 26953790.
      Citations: 1     Fields:    
    9. McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2015; 10(9):e0136851. PMID: 26325287.
      Citations: 17     Fields:    Translation:HumansAnimals
    10. Holder AM, Akcakanat A, Adkins F, Evans K, Chen H, Wei C, Milton DR, Li Y, Do KA, Janku F, Meric-Bernstam F. Epithelial to mesenchymal transition is associated with rapamycin resistance. Oncotarget. 2015 Aug 14; 6(23):19500-13. PMID: 25944619.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    11. Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst. 2015 Mar; 107(3). PMID: 25688104.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    12. Hassan B, Akcakanat A, Sangai T, Evans KW, Adkins F, Eterovic AK, Zhao H, Chen K, Chen H, Do KA, Xie SM, Holder AM, Naing A, Mills GB, Meric-Bernstam F. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget. 2014 Sep 30; 5(18):8544-57. PMID: 25261369.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    13. Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, Hwang R, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills GB. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res. 2014 Jul 15; 20(14):3870-83. PMID: 24895461.
      Citations: 21     Fields:    Translation:HumansCells
    14. Akcakanat A, Hong DS, Meric-Bernstam F. Targeting translation initiation in breast cancer. Translation (Austin). 2014; 2(1):e28968. PMID: 26779407.
      Citations:    
    15. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. Ann Oncol. 2014 Jun; 25(6):1122-7. PMID: 24669015.
      Citations: 35     Fields:    Translation:HumansCellsCTClinical Trials
    16. Blanco E, Sangai T, Wu S, Hsiao A, Ruiz-Esparza GU, Gonzalez-Delgado CA, Cara FE, Granados-Principal S, Evans KW, Akcakanat A, Wang Y, Do KA, Meric-Bernstam F, Ferrari M. Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway. Mol Ther. 2014 Jul; 22(7):1310-1319. PMID: 24569835.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    17. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr; 2(4):361-70. PMID: 24764583.
      Citations: 199     Fields:    Translation:HumansCells
    18. Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013 Oct 01; 19(19):5474-84. PMID: 24089446.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    19. Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F. Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am. 2013 Oct; 22(4):641-64. PMID: 24012393.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    20. Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, Pusztai L, Hortobagyi GN, Mills GB, Meric-Bernstam F. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat. 2013 Jan; 137(1):319-27. PMID: 23208590.
      Citations: 23     Fields:    Translation:Humans
    21. Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy BT, Hortobagyi GN, Mills GB, Gonzalez-Angulo A. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res. 2012 Oct 26; 14(5):R138. PMID: 23102376.
      Citations: 27     Fields:    Translation:HumansCells
    22. Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res. 2012 Oct 15; 18(20):5816-28. PMID: 22932669.
      Citations: 63     Fields:    Translation:HumansAnimalsCells
    23. Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012 Mar 15; 18(6):1777-89. PMID: 22422409.
      Citations: 88     Fields:    Translation:HumansAnimalsCells
    24. Emerling BM, Akcakanat A. Targeting PI3K/mTOR signaling in cancer. Cancer Res. 2011 Dec 15; 71(24):7351-9. PMID: 21987725.
      Citations: 15     Fields:    Translation:HumansCells
    25. Singh G, Akcakanat A, Sharma C, Luyimbazi D, Naff KA, Meric-Bernstam F. The effect of leucine restriction on Akt/mTOR signaling in breast cancer cell lines in vitro and in vivo. Nutr Cancer. 2011; 63(2):264-71. PMID: 21294052.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    26. Luyimbazi D, Akcakanat A, McAuliffe PF, Zhang L, Singh G, Gonzalez-Angulo AM, Chen H, Do KA, Zheng Y, Hung MC, Mills GB, Meric-Bernstam F. Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. . 2010 Oct; 9(10):2770-84. PMID: 20876744.
      Citations:    
    27. Akcakanat A, Zhang L, Tsavachidis S, Meric-Bernstam F. The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Mol Cancer. 2009 Sep 24; 8:75. PMID: 19778445.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    28. Kim D, Akcakanat A, Singh G, Sharma C, Meric-Bernstam F. Regulation and localization of ribosomal protein S6 kinase 1 isoforms. Growth Factors. 2009 Feb; 27(1):12-21. PMID: 19085255.
      Citations: 9     Fields:    Translation:HumansCells
    29. Dong J, Akcakanat A, Stivers DN, Zhang J, Kim D, Meric-Bernstam F. RNA-binding specificity of Y-box protein 1. RNA Biol. 2009 Jan-Mar; 6(1):59-64. PMID: 19098458.
      Citations: 14     Fields:    Translation:HumansCells
    30. Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, Gonzalez-Angulo A, Meric-Bernstam F. eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. . 2008 Jul; 7(7):1782-8. PMID: 18644990.
      Citations:    
    31. Akcakanat A, Sahin A, Shaye AN, Velasco MA, Meric-Bernstam F. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer. 2008 Jun; 112(11):2352-8. PMID: 18386830.
      Citations: 26     Fields:    Translation:HumansCells
    32. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer. 2008 Mar; 15(1):257-66. PMID: 18310292.
      Citations: 49     Fields:    Translation:HumansAnimalsCells
    33. Akcakanat A, Singh G, Hung MC, Meric-Bernstam F. Rapamycin regulates the phosphorylation of rictor. Biochem Biophys Res Commun. 2007 Oct 19; 362(2):330-3. PMID: 17707343.
      Citations: 26     Fields:    Translation:HumansCells
    34. Akcakanat A, Kanda T, Tanabe T, Komukai S, Yajima K, Nakagawa S, Ohashi M, Hatakeyama K. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy. Int J Cancer. 2006 Jan 01; 118(1):123-8. PMID: 16003736.
      Citations: 11     Fields:    Translation:Humans
    35. Akcakanat A, Kanda T, Koyama Y, Watanabe M, Kimura E, Yoshida Y, Komukai S, Nakagawa S, Odani S, Fujii H, Hatakeyama K. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol. 2004 Jul; 54(1):95-100. PMID: 15118836.
      Citations: 15     Fields:    Translation:Humans
    36. Unal M, Celik E, Akçali A, Akçakanat A. Diagnostic criteria of colospasm at barium enema examination. Acta Radiol. 2002 Nov; 43(6):629-30. PMID: 12485267.
      Citations:    Fields:    Translation:Humans
    37. Bozkurt MK, Agalar F, Akçakanat A. Inflammatory response to open tension-free inguinal hernioplasty versus conventional repair. Am J Surg. 2000 Jan; 179(1):76. PMID: 10737585.
      Citations:    Fields:    Translation:Humans
    38. Akcakanat A, Agalar F. Correlation between teaching ability and examination scores. Am J Surg. 1999 Nov; 178(5):434-5. PMID: 10612548.
      Citations:    Fields:    Translation:Humans
    39. Akçakanat A, Agalar F, Hayran M, Sayek I. Study of interleukin-10 and experimental acute pancreatitis. Surgery. 1997 Jun; 121(6):719-20. PMID: 9186477.
      Citations:    Fields:    Translation:Animals
    40. Agalar F, Cakmakçi M, Er M, Akçakanat A, Sayek I. Evaluation of trauma care in a developing country highlighted by a major aircraft accident. Eur J Emerg Med. 1997 Jun; 4(2):97-102. PMID: 9228451.
      Citations:    Fields:    Translation:Humans
    41. Agalar F, Akçakanat A, Hayran M, Sayek I. Pulmonary function after laparoscopic cholecystectomy in the elderly. Br J Surg. 1997 Apr; 84(4):579. PMID: 9112922.
      Citations:    Fields:    Translation:Humans
    42. Erratum. PLoS One. 11.
    43. Epithelial to mesenchymal transition is associated with rapamycin resistance. Oncotarget. 6:19500-19513.
    44. Ability to generate patient-derived Breast cancer xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes. PLoS One. 10.
    AKCAKANAT's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (211)
    Explore
    _
    Co-Authors (44)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _